NEW YORK, 25 November 2021 / PRNewswire / – Pomerantz LLP is investigating claims on behalf of investors in Gamida Cell Ltd. (“Gamida” or the “Company”) (NASDAQ: GMDA). These investors are advised to contact Robert S. Willoughby To [email protected] or 888-476-6529, ext. 7980.
The purpose of the investigation is to determine whether Gamida and any of its officers and / or directors have engaged in securities fraud or other illegal business practices.
[Click here for information about joining the class action]
At November 11, 2021, Gamida issued a press release providing an update on the Company’s meeting on the pre-biological license application (“BLA”) with the United States Food and Drug Administration for omidubicel, the treatment proposed by the United States. Blood Cancer Society. Specifically, Gamida revealed that “[t]a FDA requested Gamida Cell to provide a revised analysis of manufacturing data generated at Gamida Cell’s wholly-owned commercial manufacturing facility to demonstrate comparability with omidubicel which has been produced at clinical manufacturing sites for the phase 3 study, “a development the Company acknowledges would cause a” delay in the schedule for bringing omidubicel to patients after potential FDA approval[.]”
On this news, Gamida’s stock price fell $ 0.44, or 11.11% percent, to close at $ 3.52 per share on November 11, 2021.
The Pomerantz firm, with offices in new York, Chicago, Los Angeles, and Paris is recognized as one of the leading firms in the areas of corporate, securities and antitrust litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz was a pioneer in the field of class actions in securities. Today, more than 80 years later, Pomerantz continues the tradition it established, fighting for the rights of victims of securities fraud, breach of fiduciary duty and professional misconduct. The firm has recovered numerous multi-million dollar damages on behalf of the members of the group. See www.pomerantzlaw.com
Robert S. Willoughby
888-476-6529 ext 7980
SOURCE Pomerantz LLP